Kung A.W.-C.Rachman I.A.Adam J.M.F.Roeshadi D.Torralba T.Navarra S.Gamilla Z.Ca?ete A.de la Rosa M.KEH-SUNG TSAILin H.-Y.Soong Y.K.Lan J.-L.Hsu H.-C.Tu S.-T.Lin R.-M.Yuktanandana P.Songpatanasilp T.Ngarmukos S.Soontrapa S.Soontrapa S.Rojanasthien S.Luevitoonvechkij S.Leerapan T.Albert A.Vanbelle S.2021-03-102021-03-1020091756-1841https://scholars.lib.ntu.edu.tw/handle/123456789/551479Aim: his study assesses the impact of serum carboxy-terminal collagen crosslinks (CTX) bone marker feedback (BMF) on adherence to ibandronate treatment in Asian postmenopausal women with osteoporosis. Methods: This was a 12-month (6-monthly phased), randomized, prospective, open-label, multi-center study conducted in 596 (of 628 enrolled) postmenopausal women with osteoporosis (? 85 years old) who were na?ve, lapsed, or current bisphosphonate users. Patients were randomized into two arms: serum CTX BMF at 3 months versus no-BMF. Once-monthly 150 mg ibandronate tablet was administered for 12 months and adherence to therapy was assessed at 6 and 12 months. In addition, patient satisfaction and safety of ibandronate treatment were also assessed. Results: Serum CTX BMF at 3 months showed no impact on adherence. The proportions of adherent patients were comparable in the BMF versus no-BMF arms (92.6% vs. 96.0%, P = 0.16); overall, serum CTX levels were similar for adherent and non-adherent patients. However, BMF patients felt more informed about their osteoporosis (P < 0.001) and more satisfied (P < 0.01) than no-BMF patients. Conclusions: The Asian postmenopausal osteoporosis patients in this study had a high adherence rate to once-monthly ibandronate therapy. Use of serum CTX BMF had no further impact on increasing adherence, but increased treatment satisfaction. ? 2009 Asia Pacific League of Associations for Rheumatology and Blackwell Publishing Asia Pty Ltd.Adherence; Bone marker; Compliance; Feedback; Ibandronate; Osteoporosis[SDGs]SDG3bisphosphonic acid derivative; carboxy terminal telopeptide; ibandronic acid; aged; article; Asian; blood sampling; cardiovascular disease; clinical trial; comparative study; connective tissue disease; controlled clinical trial; controlled study; drug safety; female; gastrointestinal disease; hematologic disease; human; ileus; infection; major clinical study; metabolic disorder; multicenter study; musculoskeletal disease; neurologic disease; open study; patient compliance; patient education; patient information; patient satisfaction; postmenopause; postmenopause osteoporosis; priority journal; protein blood level; psychopathy; randomized controlled trial; Administration, Oral; Aged; Aged, 80 and over; Asian Continental Ancestry Group; Biological Markers; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Patient Satisfactionjournal article10.1111/j.1756-185X.2009.01413.x203743492-s2.0-69149106711